Starting capital
€199,347 2,000 shares
Mountvector Bio
Overview
Lifetime
1 annual account with figurespeak -€24,837 (2025)
-€24,837
lowest -€24,992 (2025)
-€24,992
peak €174,355 (2025)
€174,355
€6,061
Board2 names since 2024
2 directors and 1 other
Documentsfilings and deeds
28-08-202628 days late
2025micro format
Loss of €24,992Registered office moved from Liège to Ottignies-Louvain-la-Neuve 26-08First year with figures
Key points
from the 2025 annual accountsPosition in the sector
96.6%
Higher solvency than 92% of companies in pharmaceuticals. Sector median 45.9% · 88 companies.
2025 accounts filed 28 days after the deadlineTurnover not published (micro format)
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 3,234 companies had the same profile as Mountvector Bio has now. Each dot stands for 9 companies, two years later.
87.5%
were still trading
9.0%
stopped another way
3.3%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 3,234 companies, not a prediction for Mountvector Bio. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:1015077878
Registered office moved from Liège to Ottignies-Louvain-la-Neuve
New registered office: Fond des Més, 5/18 à 1348 Ottignies-Louvain-la-Neuve · Previous registered office: Avenue de I'Hôpital, 11 à 4000 Liège · General meeting of 30-05-2025 · Gazette deed
Incorporation
Founding capital of €199,347.36, 2,000 shares · Founder: · Appointments: (director) and (director) · published on 16-10-2024 · Gazette deed
First establishment
Mountvector Bio SRL, Avenue de l'Hôpital 11, Liège
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Mountvector Bio Ottignies-Louvain-la-Neuve | €180,416 | -€24,837 | 96.6% | - |
| RODILO Liège | €204,587 | -€2,254 | -43.9% | - |
| Groovy.Bio Evergem | €744,069 | -€17,721 | 73.2% | 0.2 |
| FYTOBELL Hasselt | €122,152 | -€55,562 | -322.9% | - |
| BIOMDRIN Schilde | €38,268 | €4,129 | 58.3% | - |
| RTLC Brussels | €107,167 | -€66 | 61.9% | - |
| HUVESEARCH Pelt | €95,955 | €1,033 | 59.9% | - |
These companies have the same main activity as Mountvector Bio: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are comparable in size and age: total assets between €38,300 and €744,000, founded between 2010 and 2024.
Official details
Source: KBO- Status
- Active since 14-10-2024Normal situation
- Registered office
- 12 active companies are registered at this address1 started in the 12 months before. Source: KBO register, as of 13 November 2026.
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201
- Establishment unit
- 2.367.582.2354000 Liège, since 14-10-2024
- Financial year end
- 31 December
- Peppol
- Reachable since 09-12-2025
Insights on Mountvector Bio
Mountvector Bio has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €174,355 and a net result of -€24,992.
Its solvency ranks better than 93% of 88 sector peers (NACE 21, financial year 2025).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette.
Financials
Annual accounts 2025
micro format, filed on 28-08-2026, 28 days late-€24,837
-€24,837
-€24,992
€174,355
96.6%
29.77
Turnover and EBIT margin are not published. The micro format does not require them.
Balance sheet
balance sheet total €180,416 on 31-12-2025What the company ownsHow it is paid for
Position in the sector
96.6%
Higher than 93% of 88 companies in 2025.
29.77
Higher than 93% of 80 companies in 2025.
-13.9%
Higher than 22% of 83 companies in 2025.
Mountvector Bio
Middle half of the sector
80% of the sector
Micro accounts in pharmaceuticals (NACE 21)
Net result: bottom quarter · Equity: middle half · Balance sheet total: middle half · Working capital: top quarter
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 |
|---|---|---|
| Balance sheet: assets | ||
20/58 |
180,416 | |
29/58 |
180,416 | |
40/41 |
3,699 | |
41 |
3,699 | |
54/58 |
172,904 | |
490/1 |
3,813 | |
| Balance sheet: equity and liabilities | ||
10/49 |
180,416 | |
10/15 |
174,355 | |
10/11 |
199,347 | |
10 |
199,347 | |
100 |
199,347 | |
14 |
-24,992 | |
17/49 |
6,061 | |
42/48 |
6,061 | |
44 |
4,661 | |
440/4 |
4,661 | |
47/48 |
1,400 | |
| Income statement | ||
9900 |
-24,837 | |
9901 |
-24,837 | |
75/76B |
0 | |
75 |
0 | |
65/66B |
156 | |
65 |
156 | |
9903 |
-24,992 | |
9904 |
-24,992 | |
9905 |
-24,992 | |
| Appropriation of the result | ||
9906 |
-24,992 | |
| Document | ||
Source: Annual accounts 2025 at the NBB, filed on 28-08-2026.
Filings
each dot is a set of accounts, on the day it reached the National Bank2025 annual accounts filed 28 days after the deadline. Filed on 28 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00441422.
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | micro format | 28-08-2026 | 2026-00441422 |
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 |
|---|---|---|
| 174,355 | ||
| 96.6% | ||
| 29.77 | ||
| 0.03 | ||
| -14.3% | ||
| -13.9% |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Insights on Mountvector Bio
Debt's share of the balance-sheet total is 3.4%.
Board & ownership
Board
2 directors, since incorporationDirector
appointed by deed of 16-10-2024
term without a fixed end
listed in the 2025 annual accounts, filed on 28-08-2026
Director
appointed by deed of 16-10-2024
term without a fixed end
listed in the 2025 annual accounts, filed on 28-08-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- Each director alonedeed of 16-10-2024
Mandates through the years
2 names, the dashed line is todayDirector
Director
Board
Mandates as a list
-
- Director, appointed by deed of 16-10-2024, still in office
-
- Director, appointed by deed of 16-10-2024, still in office
Control
Founder
This company
Mountvector Bio
Equity €174,355
Loss €24,992 in 2025
Capital
- Contribution
- €199,347.36
- Shares
- 2,000
- Contribution per share
- €99.67
- Equity per share
- €87.18 in 2025
- Source
- deed of 16-10-2024
Articles of association
deed of 16-10-2024 (in French)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Last day of April at 16:00
Shareholders
At incorporation
deed of 16-10-2024 ↗
- 2,000 shares (100%) · €199,347.36 in cash
Network & group
No group
Mountvector Bio has no parent and no holdings in its annual accounts. Mountvector Bio shares no director with another company.
Timeline
Timeline
5 events since 2024Filings
Establishments
Address
202420252026
2026
Annual accounts 2025 filed NBBmicro format · 28 days late
2025
Registered in the Peppol Directory Reachable for e-invoices through 0208:1015077878
Registered office moved from Liège to Ottignies-Louvain-la-NeuveNew registered office: Fond des Més, 5/18 à 1348 Ottignies-Louvain-la-Neuve · Previous registered office: Avenue de I'Hôpital, 11 à 4000 Liège · General meeting of 30-05-20252 points ▸
- General meeting, 30-05-2025
- Registered-office move, Fond des Més, 5/18 à 1348 Ottignies-Louvain-la-Neuve
2024
IncorporationFounding capital of €199,347.36, 2,000 shares · Founder: · Appointments: (director) and (director) · published on 16-10-20245 points ▸
- Founder,
- Founding capital, €199,347.36, 2,000 shares
- holds all the shares
- Director appointment,
- Director appointment,
- The deed holds 3 more points.
First establishment Mountvector Bio SRL, Avenue de l'Hôpital 11, Liège
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Identity
- Enterprise number
- 1015.077.878
- VAT number
- BE 1015.077.878
- Peppol ID
- 0208:1015077878
- Legal form
- Private limited company
- Status
- Active, normal situation
- Founded
- 14-10-2024
- Financial year
- ends on 31 December
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Last day of April at 16:00deed of 16-10-2024 (in French)
- Peppol
- Reachable since 09-12-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
- Name
- Mountvector Bio in French
- Entity type
- Legal entity
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 16-10-2024 (in French)
- Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
- “Avenue de l’Hôpital 11, 4000 Liège (Sart-Tilman)”deed of 16-10-2024 (in French)
Activities
NACEBEL 202521201
Manufacture of basic pharmaceutical products and pharmaceutical preparations main activity
Codes under NACEBEL 2008
21201
Manufacture of basic pharmaceutical products and pharmaceutical preparations main activity
- PurposeThe purpose describes the activities the company may carry out under its articles.
- “La fourniture de services services de développement et de fabrication de médicaments complets aux entreprises…”deed of 16-10-2024 (in French)
2 activities
- La fourniture de services services de développement et de fabrication de médicaments complets aux entreprises pharmaceutiques,biotechnologiques et de dispositifs médicaux dans le secteur de la CGT (Cell and Gene Therapy),et plus particulièrement la formulation,les services analytiques,le mélange,le revêtement,la transformation,l’emballage,la sérialisation et l’expédition.
- La mise à disposition d'une plateforme unique de services de fabrication et de développement clinique pour accélérer le développement de produits de thérapie cellulaire
Registered office and establishments
1 establishment| Establishment | Since | Unit number |
|---|---|---|
| Fond des Més 5 registered office 1348 Ottignies-Louvain-la-Neuve | ||
| Mountvector Bio SRL Avenue de l'Hôpital 11, 4000 Liège | 14-10-2024 | 2.367.582.235 |
1 former office
- Avenue de I'Hôpital, 11, 4000 Liège until 01-06-2025 · deed of 26-08-2025